I don't think its a crap shoot at all actually.....and I don't think there's any "irrational" exhuberance being expressed here either. Exhuberance? Oh yes, definitely....but imo it is perfectly rationale when you consider that phase III is on deck, and in particular the way its being structured.

Instead of having to wait for the end.....I can envision quarterly updates on how the trial is proceedeing, vis a vis how many MACE in each group....control, placebo and RVX-208. Its a little macarbre that each death in the control and placebo groups will be positive news for Resverlogix and RVX-208....but science sometimes is cruel, just not as cruel as diseases like diabetes and others which, unless a treatment is found, will continue to cause death.

Assuming RVX-208 performs as it did in the past I see a slow steady build.